Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarkers in bladder cancer.
Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK. Bryan RT, et al. Among authors: james nd. BJU Int. 2010 Mar;105(5):608-13. doi: 10.1111/j.1464-410X.2009.08880.x. Epub 2009 Sep 29. BJU Int. 2010. PMID: 19793380 Free article. Review.
Organ preservation strategies in bladder cancer.
Hussain SA, James ND. Hussain SA, et al. Among authors: james nd. Expert Rev Anticancer Ther. 2002 Dec;2(6):641-51. doi: 10.1586/14737140.2.6.641. Expert Rev Anticancer Ther. 2002. PMID: 12503210 Review.
Future development of penile cancer services in the UK.
Singh R, James ND, Watkin NA. Singh R, et al. Among authors: james nd. BJU Int. 2004 Nov;94(7):967-9. doi: 10.1111/j.1464-410X.2004.05084.x. BJU Int. 2004. PMID: 15541109 No abstract available.
Molecular markers in bladder cancer.
Hussain SA, James ND. Hussain SA, et al. Among authors: james nd. Semin Radiat Oncol. 2005 Jan;15(1):3-9. doi: 10.1016/j.semradonc.2004.07.007. Semin Radiat Oncol. 2005. PMID: 15662601 Review.
Molecular pathways in bladder cancer: part 1.
Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DM. Bryan RT, et al. Among authors: james nd. BJU Int. 2005 Mar;95(4):485-90. doi: 10.1111/j.1464-410X.2005.05325.x. BJU Int. 2005. PMID: 15705065 Review. No abstract available.
Molecular pathways in bladder cancer: part 2.
Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DM. Bryan RT, et al. Among authors: james nd. BJU Int. 2005 Mar;95(4):491-6. doi: 10.1111/j.1464-410X.2005.05326.x. BJU Int. 2005. PMID: 15705066 Review. No abstract available.
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P, McIntosh S, Morris T, Phung D, Dawson NA. James ND, et al. BJU Int. 2010 Oct;106(7):966-73. doi: 10.1111/j.1464-410X.2010.09638.x. BJU Int. 2010. PMID: 20840318 Clinical Trial.
Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer.
Bryan RT, Wei W, Shimwell NJ, Collins SI, Hussain SA, Billingham LJ, Murray PG, Deshmukh N, James ND, Wallace DM, Johnson PJ, Zeegers MP, Cheng KK, Martin A, Ward DG. Bryan RT, et al. Among authors: james nd. Proteomics Clin Appl. 2011 Oct;5(9-10):493-503. doi: 10.1002/prca.201100011. Epub 2011 Sep 6. Proteomics Clin Appl. 2011. PMID: 21805675
222 results